Reimbursement for Oncology Treatment

Video

For High-Definition, Click

The now-repealed Sustainable Growth Rate (SGR) formula was created via the Balanced Budget Act of 1997 to prevent Medicare physician payments from ballooning beyond the government’s ability to pay, explains Pecora. Unfortunately, the SGR caused huge payment uncertainty for physicians.

It was repealed in March via the passage of the Medicare Access and CHIP Reauthorization Act of 2015, which established performance incentives to encourage physicians to improve health outcomes and participate in cost-saving models of care.

Historically, there used to be a substantial margin on oncology medication prices that enabled oncologists to hire staff and enjoy an acceptable standard of living, comments Pecora. The pendulum has swung the other way, and margins on care delivery have shrunk dramatically, placing “incredible stress” on the healthcare system, he says.

The rise of immunotherapy agents, he adds, has compounded the problem. They work, but are incredibly expensive. Therefore, their increasing use for an array of cancer types and for combination therapy may lead to a higher cost burden, he explains.

Related Videos
Arya Amini, MD
Adrianna Masters, MD, PhD,
Chul Kim, MD, MPH
Andrew Ip, MD
In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.
In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.
In this seventh episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss how artificial intelligence tools may be utilized to improve wait time for treatment, to provide more time for provider-patient interactions, and more.
In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.
In this sixth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss potential opportunities to leverage artificial intelligence tools in cancer screening, diagnosis, staging, and prognosis.
Christopher M. Gallagher, MD